Magnetic Resonance Imaging of Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by Stanford University
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Stanford University Identifier:
First received: December 17, 2009
Last updated: August 5, 2015
Last verified: August 2015
To compare magnetic resonance imaging (MRI) with more well established diagnostic imaging techniques to determine which method best finds and defines breast cancer.

Condition Intervention
Breast Cancer
Breast Cancer Non-invasive Breast Cancer
Procedure: MRI

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Magnetic Resonance Imaging of Breast Cancer

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • To compare magnetic resonance imaging (MRI) with more well established diagnostic imaging techniques to determine which method best finds and defines breast cancer. [ Time Frame: Length of one MRI scan ] [ Designated as safety issue: No ]

Estimated Enrollment: 445
Study Start Date: April 1995
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Contrast-enhanced MRI using the standard department of Radiology MRI screening procedures. The duration of scanning may be variable, but will not exceed 90 minutes.
Procedure: MRI


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Women referred for MRI or mammography by their physicians to the Stanford department of Radiology or from referrals from the Stanford Oncology Divison, the Stanford Radiation Oncology Department, and the Stanford Surgery Department.

Inclusion Criteria:

Women will have already undergone a breast physical examination, will have had mammography within three months of their MR studies, and if they have not had this study, will mammography after their MR examinations.

Women with palpable or mammographically-detected suspect breast lesions with or without breast implants will be imaged. Women who are at high risk for breast cancer may also be included since these women commonly require breast MRI screening. Since some patients may have had recent core-needle biopsies and may have recent post-needle biopsy changes but plan follow-up mastectomies or excision of the biopsy site (complete re-excision), we will include this group. This will allow us to obtain the broad spectrum of post-needle biopsy findings since it is a common procedure that is used prior to biopsy to evaluate patients for potential cancer multicentricity or multifocality. Women who have already undergone lumpectomy for breast cancer and have post-biopsy/post-radiation changes will be eligible if they have mammographically-detected or palpable breast abnormalities which are sufficiently suspicious to merit core needle or surgical biopsy.

Exclusion Criteria:

The low incidence of male breast cancer precludes a significant participation of men in the program and men will be excluded. Patients must be able to complete an MR examination. Subjects will be interviewed by one of the investigators for the usual contraindications to MR including pacemakers, metallic implants, severe claustrophobia, aneurysm clips, pregnancy, current lactation, or other conditions precluding proximity to a strong magnetic field. These patients will be excluded if these contraindications are present.

Other patients will be excluded from the MR study if they have had an enhanced MR procedure within 48 hours, had iodinated contrast within six hours, had known sensitivity to MR contrast agents, are not likely to complete the study in full or have another clinical reason which would preclude participation in the protocol.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01035112

United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Sumita Sood    650-723-0618   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: Bruce Lewis Daniel         
Sub-Investigator: Brian Andrew Hargreaves         
Sub-Investigator: Robert J Herfkens         
Sponsors and Collaborators
Stanford University
National Institutes of Health (NIH)
Principal Investigator: Bruce Lewis Daniel Stanford University
  More Information

No publications provided

Responsible Party: Stanford University Identifier: NCT01035112     History of Changes
Other Study ID Numbers: BRSNSTU0004, 13IB-0074, 75763, SU-10312007-769, CA66785
Study First Received: December 17, 2009
Last Updated: August 5, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases processed this record on November 27, 2015